 -- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated -- -- Non- A bsorption o f ALLN-346 Demonstrated -- -- Advancing to Phase 1b Multiple - Ascending Dose Study and Phase 2 Proof-of-Concept Trial ; Initial Data from Both Studies Expected in Second Half of 2021 -- NEWTON, Mass., Nov. 30, 2020 GLOBE NEWSWIRE -- Allena Pharmaceuticals, Inc. NASDAQ: ALNA, a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced clinical data from its Phase 1 trial of ALLN-346 in healthy volunteers. ALLN-346 is an investigational, orally administered, novel urate-degrading enzyme that has been designed for activity and stability in the gastrointestinal GI tract, and is intended for the treatment of hyperuricemia in patients with gout and chronic kidney disease CKD. 